U.S. Equity Benchmarks, Gold, Silver Extended Young‑Year Rally – January 6, 2025 -( $GOVX $INTC $LLY $MCD $MODD $MU $OKLO $OPEN $PLTR $RIO $TSM Rise!)

Wall Street closed Tuesday with a spring in its step and a raised eyebrow, as blue chips powered to fresh records while small caps joined the party. A looming Supreme Court ruling on President Trump’s tariffs, another shutdown deadline, and a packed Fed calendar gave the session a distinct “new year, same macro drama” feel.

Indexes: Big Caps Take a Bow

The major U.S. benchmarks extended their young‑year rally, led once again by the market’s largest and loudest names.

• The S&P 500 climbed roughly 0.62% to its first record close of 2026 at 6,944.82, aided by strength in technology and healthcare, and is now up about 1.5% year to date.
• The Dow Jones Industrial Average rose about .99% (roughly 485 points) to finish above 49,000 for the first time, as industrial and consumer bellwethers extended Monday’s fireworks.
• The Nasdaq gained about 1.65% on the day to close at 23,547.17, with AI and semiconductor names again doing the heavy lifting.
• The Russell 2000 rose 1.37% to close at 2,582.90.

Macro: Quiet Tape, Loud Backdrop

The economic calendar delivered more noise than signal, but the policy backdrop stayed front and center.

• Scheduled U.S. releases were second‑tier, including PMI readings and routine bill auctions, leaving traders focused on the upcoming international trade and labor data later in the week.
• The Fed’s benchmark rate stands at about 3.75%, with the next FOMC decision due on January 28 and additional meetings slated for March 18 and April 29, keeping front‑end rates well‑anchored even as markets price gradual cuts through 2026.

Policy: Tariffs, Shutdowns, and the Fed

Washington once again played its familiar role as market background risk, if not immediate catalyst.

• On trade, the Supreme Court set Friday for opinions in closely watched cases that could determine the fate of President Trump’s “Liberation Day” tariffs, putting as much as roughly $130 billion‑plus of duties at legal risk and raising the prospect of refunds for importers.
• On fiscal matters, the government remains funded only through January 30 under a stopgap deal that ended last year’s 43‑day shutdown, and lawmakers returned to Washington this week with another funding scramble already dominating the agenda.
• For monetary policy, the yield curve remains relatively flat to modestly positive versus last year’s deep inversion, and Fed‑tracked models now put the 10‑year yield near the low‑4% range at 4.178% & the 2-yr at 3.471% with recession odds easing into the mid‑teens over the next year.

Commodities and Crypto: Glitter and Grit

Safe‑haven trades and geopolitical risk kept the tape lively across metals, energy and digital assets.

• Gold prices closed at 4,507.30, +1.25% and flirting with fresh highs as investors balanced tariff uncertainty and renewed geopolitical tension
• Silver continued its parabolic turn, trading to $81.305, +6.06% per ounce after a multi‑month surge of more than 30% and a year‑over‑year gain north of 150%, making bullion investors feel unusually witty at cocktail parties.
• Crude Oil prices pushed lower today to close at $56.97/bbl down 2.37% after recent U.S. action against Venezuela
• Bitcoin traded in the low‑to‑mid $93,000s somewhat sustaining a strong uptrend that continues to encourage talk of “digital gold” in a world where the analog variety already sits near records.

Corporate Tape: AI Aristocrats and Old Economy Stalwarts

Mega‑cap tech and AI infrastructure remained in fashion, as the Street continued to anoint long‑term winners in chips and cloud.

• Eli Lilly (LLY, $1,064.04, +2.16%): The drugmaker, now synonymous with the weight‑loss boom, traded with the broader healthcare bid as investors continued to treat obesity and diabetes franchises as durable growth engines into 2026.
• TSMC (TSM, $327.43, +1.61%) and Nvidia (NVDA): AI infrastructure darlings remained firmly in the market’s good graces, with analysts reiterating bullish views on 2026 capex cycles and positioning Nvidia as the “king of AI” and Micron‑like names as key memory beneficiaries.
• Micron (MU, $343.43, +10.02%): Commentary continued to frame Micron as the “Nvidia of memory,” with its latest fiscal‑2026 update highlighting upside in AI‑driven DRAM and HBM demand, keeping the stock central to the AI‑hardware narrative.
• Apple (AAPL) and Tesla (TSLA): Both remained under close watch and moved lower as key members of the AI‑and‑auto complex, with recent analyst calls emphasizing software, services, and autonomy as the next leg of growth; Tuesday’s trading reflected that continuing tug‑of‑war more than any single headline.
• Broadcom (AVGO, $343.77, +.10%) and Meta (META, $660.62, +.28%): AI‑linked names continued to benefit from expectations of another year of surging data‑center spend and ad‑supported monetization of AI features, leaving both at the center of “AI plus cash‑flow” strategies.
• Nokia (NOK) and Intel (INTC, $40.04, +1.70%): Legacy hardware players saw renewed interest tied to 5G, networking and advanced packaging, with recent upgrades citing a multi‑year AI‑data‑infrastructure buildout; Intel in particular drew praise for its foundry and packaging roadmap into 2026.
• McDonald’s (MCD, $302.77, +.97%): The Golden Arches continued to be treated as a defensive growth story, with investors focused on pricing power and digital ordering, making the stock a quiet beneficiary of any renewed consumer‑spending jitters.
• Rio Tinto (RIO, $85.23, +2.43%): The miner participated in the broader commodities‑and‑metals theme, as surging precious metals and ongoing demand for critical minerals kept interest elevated across diversified resource names.
• Oracle (ORCL, $193.75, +.60%): Oracle’s pitch as a chip‑neutral, one‑stop AI infrastructure shop remained a market talking point, with recent analysis highlighting its embedded AI strategy and potential to surprise on cloud‑related growth.
• Oklo (OKLO, $95.60, +7.01%): The advanced‑nuclear developer stayed on the speculative AI‑energy radar as investors looked at small‑modular reactors as a potential long‑term solution for data‑center power demands, though trading remained headline‑driven rather than earnings‑driven at this stage.
• Opendoor (OPEN, $6.93, +9.81%): The iBuyer’s shares remained tethered to rate expectations and housing turnover; with markets pricing eventual Fed cuts, the stock continued to trade as a leveraged bet on a thaw in U.S. housing activity.
• Palantir (PLTR, $179.71, +3.26%): A perennial AI‑software favorite, Palantir stayed in focus as investors bet on expanded government and commercial AI contracts, with the stock often grouped among top AI names to own into 2026.

Deals, IPOs, and Listings

Corporate finance desks eased into 2026, but the calendar still produced a few debuts and vehicles for future deal‑making.

• On the IPO front, Art Technology Acquisition Corp. (ARTC) priced on Nasdaq and Black Spade Acquisition III Co. (BIII) priced on the NYSE, adding fresh special‑purpose capital to the hunt for targets in technology and consumer sectors.
• Beyond those SPAC‑style listings, the U.S. new‑issue pipeline for the week includes Aktis Oncology and several smaller international and uplisting deals, but Tuesday itself saw no marquee operating‑company debuts.
• Major strategic M&A, buyouts or transformational acquisitions were quiet on the day, suggesting that dealmakers, unlike the Dow, may still be recovering from their holiday travel.

Vista Partners Watchlist Updates

Modular Medical, Inc. (Nasdaq: MODD., $.4034, +3.60%), a leader in innovative insulin delivery technology targeting the $3 billion adult “almost-pumpers” diabetes market with user-friendly, affordable patch pumps, announced (Dec. 10) that it had priced an underwritten public offering (the “offering”) of 12,173,000 shares of its common stock and accompanying warrants to purchase 6,086,500 shares of its common stock. Each two shares of common stock are being offered and sold together with one accompanying warrant at a combined offering at a price of $0.77, yielding an effective price of $0.38 per share and $0.01 per warrant. The warrants will have an exercise price of $0.45 per share, are exercisable immediately upon issuance and will expire five years following the date of issuance. In connection with the offering, Modular Medical has granted the underwriter a 30-day option to purchase up to an additional 15% of common shares and/or warrants at the public offering price, less underwriting discounts and commissions. The over-allotment option may be elected with respect to, at the underwriter’s sole discretion, shares and warrants together, solely shares, solely warrants, or any combination thereof. Newbridge Securities Corporation is acting as the sole bookrunner for the offering. Assuming no exercise of the over-allotment option, the gross proceeds to the Company from the offering are expected to be approximately $4.68 million, before deducting underwriting discounts, commissions, and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund operations and for working capital and general corporate purposes, including capital expenditures.

On Nov. 17, Modular announced Institutional Review Board (“IRB”) approval to conduct an in-house study of its next-generation Pivot™ insulin delivery system using insulin on people with diabetes (the “Study”). Pursuant to U.S. Food and Drug Administration (“FDA”) regulations, an IRB is a group that has been formally designated to review and monitor biomedical research involving human subjects. The Study will simulate real-world conditions by delivering insulin to adult participants to gather critical data on device function and usability and obtain user feedback. Modular Medical’s Pivot tubeless patch pump aims to enhance accessibility for underserved patients with diabetes and drive market penetration and expansion.

On Nov. 14, Modular Medical announced the 510(k) premarket submission of its next generation Pivot™ tubeless patch pump to the U.S. Food and Drug Administration (the “FDA”). The Company expects to commence the commercial launch of its Pivot pump in Q1 2026. On Nov. 3, Modular Medical the successful validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, $7.44), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, announced (Nov. 13) the second set of 52-week follow up data from its ongoing Phase 1b/2a RESOLVE trial evaluating a single administration EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). James A. Helliwell, Chief Executive Officer of Eupraxia stated,“These data further highlight the strong durability and tolerability profile of EP-104GI, reinforcing its potential to become a convenient, once-a-year treatment that fits seamlessly into routine disease management by aligning with annual patient endoscopies. The Cohorts 5 & 6 patients – the only groups to have reached 52 weeks in the trial – are demonstrating levels of symptom relief that is durable and clinically meaningful – we are very encouraged by this outcome. We’re also pleased that our previously announced 52-week data were presented as a late-breaking presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG). These new results build on that momentum. Given that current EoE therapies often struggle with long-term adherence, we believe a durable, once-yearly treatment could meaningfully improve patient outcomes and establish EP-104GI as a preferred option for both physicians and their patients.”

GeoVax Labs, Inc. (Nasdaq: GOVX, $.2175. +14.47%), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer.

GeoVax is heading into the 44th Annual J.P. Morgan Healthcare Conference week (“JPM2026”) in San Francisco, CA Jan. 12-15 with the kind of narrative biotech investors typically like to hear: a differentiated platform, large funded trials lining up, and multiple shots on goal in both infectious disease and oncology. The company is leaning into its MVA platform as a potential franchise engine rather than a one‑product science experiment. Specifically, investors can meet David Dodd, Chairman & CEO of GeoVax, during his presentation at the Hilton Union Square, 333 O’Farrell Street, Yosemite A (Ballroom Level), San Francisco, CA on January 13, 2026, 2:30 pm PST.

GeoVax announced (Dec. 19) that it has entered into definitive securities purchase agreements with several institutional and individual investors for the purchase and sale of approximately 13.2 million units, each comprised of one share of the Company’s common stock and warrants, as described below, to purchase shares of the Company’s common stock, at a price of $0.245 per unit in a public offering. The Company will issue warrants to purchase up to approximately 26.5 million shares of common stock. The warrants will have an exercise price of $0.245 per share, will be exercisable immediately following the date of issuance and will have a term of five years following the date of issuance. Roth Capital Partners is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from this offering are expected to be approximately $3.2 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. The closing of the offering is expected to occur on or about December 22, 2025, subject to the satisfaction of customary closing conditions.

GeoVax announced (Dec. 18) the publication of a peer-reviewed article in Frontiers in Immunology titled: “Multi-antigen MVA-vectored SARS-CoV-2 vaccine, GEO-CM04S1, induces cross-protective immune responses to ancestral and Omicron variants.” The study provides definitive preclinical evidence that GeoVax’s multi-antigen COVID-19 vaccine candidate, GEO-CM04S1, delivers full cross-variant protection, driven predominantly by robust T-cell responses, even in the absence of neutralizing antibodies. The findings reinforce the design philosophy behind GeoVax’s MVA-based, multi-antigen platform and provide mechanistic insight that is increasingly relevant for immunocompromised individuals, who often fail to respond optimally to the first-generation COVID-19 vaccines.

GeoVax announced (Dec. 17) the successful completion of fill-finish for the initial clinical batch of GEO-MVA, its next-generation Mpox/smallpox vaccine. The product has now entered final release evaluation, the concluding quality-control and compliance process required before shipment for clinical use, positioning the Company for Phase 3 immunobridging trial start-up activities in Q1 2026. Fill-finish – the sterile, cGMP-regulated process of filling, sealing, and packaging vaccine vials – marks the last manufacturing step before a vaccine may enter clinical study supply channels. With fill-finish complete and GEO-MVA now undergoing final release evaluation, GeoVax has moved into the final pre-clinical-deployment phase of its EMA-aligned clinical program. In June 2025, the European Medicines Agency (EMA) Scientific Advice confirmed that a single Phase 3 immunobridging study demonstrating immune comparability to the approved MVA vaccine, Imvanex(R), would be sufficient to evaluate GEO-MVA’s efficacy. This provides a clear, accelerated regulatory path to licensure. This milestone coincides with increasing Mpox activity globally – including expanding Clade I outbreaks in Africa and emerging cases in the United States – exposing vulnerabilities associated with global dependence on a sole foreign MVA vaccine supplier. GEO-MVA is designed to expand supply, diversify sources, and strengthen biodefense infrastructure.

Volato Group, Inc. (NYSE American: SOAR, $.72, +0.0%) and M2i Global, Inc. (MTWO, $.0655), a company specializing in the development and execution of a complete global value supply chain for critical minerals, recently announced key developments in its pending all-stock merger with M2i Global, Inc.. Volato has filed the Registration Statement on Form S-4 with the U.S. Securities and Exchange Commission (the “SEC”), following the SEC’s completion of its review of the initial confidential submission. With the reopening of federal agencies following the recent government shutdown, both companies now anticipate closing the merger in the first quarter of 2026, pending completion of SEC review and shareholder approval.

Volato Group, Inc. today (Dec. 29) announced the appointment of Alan D. Gaines to its Board of Directors, effective immediately. Mr. Gaines will also serve as Chairman of the Audit Committee.

On Dec. 23, Volato Group, Inc. announced preliminary financial guidance for the fourth quarter and full year ending December 31, 2025, reflecting continued execution against its strategic and balance sheet objectives. For the fourth quarter of 2025, Volato expects to report revenue between $27 million and $28 million. For the full year 2025, the Company anticipates total revenue between $78 million and $79 million, with net income of $6 million to $8 million. These results reflect a year of meaningful progression aligning operational performance with Volato’s long-term growth initiatives and advancing its pending merger with M2i Global, Inc. (OTC: MTWO). During 2025, Volato also made substantial progress strengthening its balance sheet. As of September 30, 2025, the Company reduced total liabilities to $9.5 million, satisfying the debt reduction condition required under its pending merger agreement with M2i Global, Inc. (OTC: MTWO). Volato expects continued improvement in its capital structure as it advances toward a targeted first-quarter 2026 closing of the transaction. “Our 2025 results reflect a year of transformation and disciplined balance sheet execution,” said Mark Heinen, Chief Financial Officer of Volato. “We made significant progress reducing liabilities while sharpening our focus on scalable, technology-driven businesses that are designed to complement and strengthen the M2i Global platform over the long term.”

On Dec. 18, Volato Group, Inc. and M2i Global, Inc. announced that they applaud the recent December 11, 2025 announcement from the U.S. Department of State whereby Pax Silica, a U.S.-led strategic initiative to build a secure, prosperous, and innovation driven silicon supply chain—from critical minerals and energy inputs to advanced manufacturing, semiconductors, AI infrastructure, and logistics, was formed.

Volato Group, Inc. announced recently that it has set a preliminary date of February 26, 2026 and preliminary record date of January 17, 2026 for a special meeting of shareholders to vote on the proposed merger with M2i Global, Inc. (MTWO) and related matters. The preliminary meeting date and record date remain subject to applicable regulatory and exchange requirements, including the effectiveness of Volato’s Registration Statement on Form S-4 (File No. 333-292132) (the “Registration Statement”) filed with the U.S. Securities and Exchange Commission (“SEC”) and the mailing of definitive proxy materials to shareholders. The proposed merger creates a combined company built for scale. M2i Global brings a platform focused on critical minerals and national supply chain resilience, while Volato contributes proven aviation technology, software capability, and an established track record of operational execution. Together, the companies aim to participate in a U.S. critical minerals market estimated at more than $320 billion annually.

Serina Therapeutics (NYSE American: SER, $2.08, +o.o%), Alabama-based biotech is betting its proprietary POZ platform and reimagined approach to apomorphine delivery may redefine the treatment paradigm for patients who have exhausted standard oral therapies. On Dec. 11, Serina announced the appointment of Joshua Thomas, Ph.D., as Vice President and Head of Chemistry. He will oversee internal and external chemistry efforts to optimize POZ-based candidates, supporting efficient translation from discovery through development.

On Dec. 10, Serina announced that it has submitted a complete response to the U.S. Food and Drug Administration’s (“FDA”) clinical hold letter for SER-252, the Company’s lead program for advanced Parkinson’s disease. As previously disclosed, the FDA placed the Company’s Investigational New Drug (“IND”) application for SER-252 on clinical hold pending additional information related to a commonly used formulation excipient. On November 25, 2025, the FDA issued a formal full clinical hold letter specifying the information required to permit initiation of the planned Phase 1b registrational study, SER-252-1b. The issues identified by the FDA do not relate to the apomorphine active drug substance, its mechanism of action, the use of the enFuse device (Enable Injections) or the broader 505(b)(2) NDA development pathway previously discussed with the Agency.

The InterGroup Corporation (NASDAQ: INTG, $25.33) reported (Nov. 17) results for the three months ended September 30, 2025. John V. Winfield, Chairman and Chief Executive Officer, said: “We continue to observe signs of stabilization and recovery across the San Francisco hospitality market, including improving convention calendars, tourism indicators, and business travel activity. On the investment side, our marketable securities activity remained modest with a small net gain, consistent with our emphasis on liquidity and risk discipline.”

DoubleVerify Holdings Inc. (DV) closed at $10.96. DoubleVerify, which built its franchise on media verification and ad performance analytics, is now the first badged TikTok Marketing Partner focused specifically on attention measurement, tapping impression-level signals from the platform. Brands gain a granular view of how exposure and user interaction come together across TikTok formats, ad sets, creatives, and objectives, effectively treating every swipe as a tiny A/B test.

The Sources

1. https://www.reuters.com/legal/government/with-trumps-tariffs-line-us-supreme-court-plans-rulings-friday-2026-01-06/
2. https://www.reuters.com/world/us/us-tariffs-that-are-risk-court-ordered-refunds-exceed-1335-billion-2026-01-06/
3. https://nctr.org/the-government-shutdown-is-over-for-now-what-is-going-on/
4. https://www.forvismazars.us/forsights/2026/01/from-the-hill-january-6-2025
5. https://www.federalreserve.gov/monetarypolicy/fomccalendars.htm
6. https://www.stamfordadvocate.com/business/article/how-major-us-stock-indexes-fared-tuesday-1-6-2026-21280115.php
7. https://www.wsj.com/finance/stocks/global-stocks-markets-dow-news-01-06-2026-085f5356
8. https://finance.yahoo.com/news/live/stock-market-today-dow-sp-500-nasdaq-nudge-higher-after-dows-rally-to-record-143551914.html
9. https://www.thestreet.com/latest-news/stock-market-today-jan-6-nasdaq-sp-500-continue-new-year-rally
10. https://us.econoday.com
11. https://finance.yahoo.com/calendar/economic?day=2026-01-06
12. https://fred.stlouisfed.org/releases/calendar
13. https://tradingeconomics.com/united-states/interest-rate
14. https://essentialhospitals.org/on-the-hill-possibility-of-another-government-shutdown-looms/
15. https://finance.yahoo.com/news/supreme-court-sets-friday-opinion-154444055.html
16. https://www.thompsonhinesmartrade.com/2026/01/cbp-to-issue-all-refunds-electronically-starting-february-6-2026/
17. https://www.usnews.com/news/politics/articles/2026-01-06/with-trumps-tariffs-on-the-line-us-supreme-court-plans-rulings-for-friday
18. https://www.hklaw.com/en/insights/publications/2026/01/holland-knight-health-dose-january-6-2026
19. https://www.clevelandfed.org/indicators-and-data/yield-curve-and-predicted-gdp-growth
20. https://www.timesleaderonline.com/news/business/2026/01/wall-street-gains-ground-as-crude-prices-and-oil-company-stocks-rise/
21. https://www.investopedia.com/5-things-to-know-before-the-stock-market-opens-january-6-2026-11879733
22. https://www.ishares.com/us/insights/fed-outlook-2026-interest-rate-forecast
23. https://www.exchangerates.org.uk/news/44905/2026-01-06-us-dollar-gold-stocks-bitcoin-oil-prices-higher-us-strike-venezuela.html
24. https://fortune.com/article/current-price-of-silver-1-6-2026/
25. https://www.forbes.com/sites/digital-assets/2025/12/27/us-dollar-collapse-crisis-warning-2026-gold-and-silver-surge-predicted-to-blow-up-the-bitcoin-price/
26. https://seekingalpha.com/article/4856778-5-predictions-for-2026-gold-silver-bitcoin-ai-geopolitics
27. https://forex24.pro/bitcoin-forecast/bitcoin-forecast-and-btc-usd-analysis-for-january-6-2026/
28. https://www.investing.com/analysis/5-stocks-set-to-start-strong-in-january-and-lead-through-2026-200672453
29. https://finance.yahoo.com/news/3-best-artificial-intelligence-stocks-052000158.html
30. https://finance.yahoo.com/news/high-growth-tech-stocks-us-113808859.html
31. https://finance.yahoo.com/news/4-top-tech-stocks-buy-222000338.html
32. https://www.heygotrade.com/en/news/3-potential-stocks-for-2026-top-big-tech-analysis
33. https://www.nasdaq.com/articles/could-january-spark-next-big-rally-ai-stocks
34. https://finviz.com/news/263255/5-stocks-set-to-start-strong-in-january-and-lead-through-2026
35. https://www.cnbc.com/2026/01/05/monday-biggest-wall-street-stocks-like-nvidia.html
36. https://www.iposcoop.com/ipo-calendar/
37. https://stockanalysis.com/ipos/calendar/
38. https://www.nasdaqtrader.com/TraderNews.aspx?id=ETP2026-01
39. https://www.nasdaq.com/market-activity/ipos
40. https://www.marketwatch.com/tools/ipo-calendar
41. https://www.aljazeera.com/economy/2026/1/6/us-supreme-court-expected-to-rule-on-tariffs-on-friday
42. https://www.usatoday.com/story/money/2026/01/05/tariff-stimulus-checks-january-2026/88032120007/
43. https://fortune.com/2026/01/06/why-tariffs-cut-inflation-san-francisco-federal-reserve-taxes-affordability/
44. https://www.tradecomplianceresourcehub.com/2026/01/02/trump-2-0-tariff-tracker/
45. https://www.youtube.com/watch?v=0d1QCWtJUoM
46. https://www.scotusblog.com/2026/01/scotustoday-for-monday-january-5/
47. https://home.treasury.gov/resource-center/data-chart-center/interest-rates/TextView?type=daily_treasury_yield_curve&field_tdr_date_value=2026
48. https://www.forbes.com/sites/digital-assets/2026/01/04/just-the-beginning-bitcoin-and-crypto-suddenly-braced-for-a-critical-173-trillion-oil-price-shock/
49. https://lasvegassun.com/news/2026/jan/06/how-major-us-stock-indexes-fared-tuesday-162026/
50. https://navellier.com/1-6-26-talking-markets-with-chatgpt/
51. https://www.bloomberg.com/news/articles/2026-01-05/stock-market-today-dow-s-p-live-updates
52. https://www.youtube.com/watch?v=3m4bW1fJ7P4
53. https://www.marketwatch.com/economy-politics/calendar
54. https://tradingeconomics.com/united-states/calendar
55. https://forex.tradingcharts.com/economic_calendar/2026-01-06.html?code=USD
56. https://www.census.gov/economic-indicators/calendar-listview.html
57. https://finance.yahoo.com/calendar/ipo?from=2026-01-19&to=2026-01-24&day=2026-01-06
58. https://www.bls.gov/schedule/